There are currently 48 active clinical trials seeking participants for Solid Tumors research studies. The states with the highest number of trials for Solid Tumors participants are Texas, California, New York and Tennessee.
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324
Recruiting
To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/04/2024
Locations: The Angeles Clinic and Research Institute, Los Angeles, California +29 locations
Conditions: Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
Register for Updates
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors
NCT05262400
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with breast cancer. This clinical study consists of 2 parts (part 1 and part 2). In part 1, we are seeking participants who: Have been diagnosed with Breast Cancer (BC) of either types: Have HR+, HER2- BC Refractory HR-positive/HER2-positive BC Have other solid tumors other than BC In part 2, we are seeking participants who: -Have HR-positive/HER2-ne... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Administrative Address: UCLA Hematology/Oncology, Los Angeles, California +50 locations
Conditions: Breast Cancer, Solid Tumors
Register for Updates
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
NCT05536141
Recruiting
The purpose of this study is to evaluate the safety and tolerability of: AB521 when taken alone in participants with advanced solid tumor malignancies and clear cell renal cell carcinoma (ccRCC) during the dose escalation stage; and AB521 monotherapy and AB521 in combination with cabozantinib in participants with ccRCC in the dose expansion stage
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: UCLA, Santa Monica, California +16 locations
Conditions: Clear Cell Renal Cell Carcinoma, Solid Tumors
Register for Updates
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT04250155
Recruiting
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 alone or in combination with a checkpoint inhibitor treatment in participants with locally advanced or metastatic solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Honor Health Research Institute, Scottsdale, Arizona +31 locations
Conditions: Solid Tumors
Register for Updates
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT03313778
Recruiting
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/31/2024
Locations: University of Arizona, Tucson, Arizona +12 locations
Conditions: Solid Tumors
Register for Updates
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05325866
Recruiting
The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/29/2024
Locations: City of Hope National Medical Center, Duarte, California +109 locations
Conditions: Solid Tumors
Register for Updates
Screening Study for Participants With Malignant Tumors
NCT05419375
Recruiting
The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/29/2024
Locations: Arizona Oncology Associates, PC - HOPE, Tucson, Arizona +127 locations
Conditions: Solid Tumors
Register for Updates
QTX3034 in Patients With KRAS G12D Mutation
NCT06227377
Recruiting
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/28/2024
Locations: Duke University, Durham, North Carolina +4 locations
Conditions: Solid Tumors
Register for Updates
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
NCT04337177
Recruiting
A pilot pharmacokinetic trial to determine the safety and efficacy of a flavored, orally administered irinotecan VAL-413 (Orotecan®) given with temozolomide for treatment of recurrent pediatric solid tumors including but not limited to neuroblastoma, rhabdomyosarcoma, Ewing sarcoma, hepatoblastoma and medulloblastoma
Gender:
All
Ages:
Between 1 year and 30 years
Trial Updated:
05/27/2024
Locations: UCSF, Mission Bay - Benioff Children's Hospital, San Francisco, California +7 locations
Conditions: Solid Tumors, Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma, Hepatoblastoma, Medulloblastoma
Register for Updates
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
NCT04570423
Recruiting
The purpose of this study is to evaluate the safety and pharmacokinetics of eflapegrastim in pediatric participants with solid tumors or lymphoma and treated with myelosuppressive chemotherapy.
Gender:
All
Ages:
Between 1 month and 17 years
Trial Updated:
05/15/2024
Locations: New York Medical College, Valhalla, New York +3 locations
Conditions: Solid Tumors, Lymphoma
Register for Updates
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
NCT05731947
Recruiting
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and anti-tumor activity of revumenib in participants with colorectal cancer (CRC) or other solid tumors who have failed at least 1 prior line of therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Honor Health Research Institute, Scottsdale, Arizona +4 locations
Conditions: Colorectal Cancer, Solid Tumors
Register for Updates
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
NCT06082960
Recruiting
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors Identify the maximum tolerated dose (MTD)... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: Smilow Cancer Hospital Phase 1 Unit, New Haven, Connecticut +5 locations
Conditions: Solid Tumors
Register for Updates